Grace Therapeutics, Inc.
GRCE Healthcare Biotechnology
In the quarter to June 2026, EPS fell 333.3% and free cash flow fell 78.9%, each against the same quarter a year earlier. Revenue growth for ten consecutive years; insiders bought in the last twelve months.
Follow GRCE
Grace Therapeutics, Inc. (GRCE) Altman Z-score
Grace Therapeutics, Inc.'s Altman Z-score for fiscal 2021 is 3.31, in the safe zone (above 2.99).
Altman Z-score, annual
Embed this chart
Annual newest first
| Period | Altman Z-score | Change (points) |
|---|---|---|
| FY2021 | 3.31 | (3.70) |
| FY2016 | 7.01 | (14.29) |
| FY2015 | 21.30 | — |
How fiscal 2021’s score is made up
| Component | This year | Year before | Result | Points |
|---|---|---|---|---|
| Working capital / total assets | 0.97 | — | 1.17 | |
| Retained earnings / total assets | (2.34) | — | −3.27 | |
| EBIT / total assets | (0.26) | — | −0.87 | |
| Market value of equity / total liabilities | 10.47 | — | 6.28 | |
| Sales / total assets | 0.00 | — | 0.00 | |
| Altman Z-score | Safe zone | 3.31 | ||
| Z″ Variant for non-manufacturing and asset-light companies (drops the sales/assets term, uses book equity) | Safe zone | 5.59 | ||
How the Altman Z-score works
Z = 1.2 × working capital ÷ total assets + 1.4 × retained earnings ÷ total assets + 3.3 × EBIT ÷ total assets + 0.6 × market value of equity ÷ total liabilities + 1.0 × revenue ÷ total assets (Altman, 1968). The market value of equity is the close on the last trading day of the fiscal year times weighted basic shares.
Z″ = 6.56 × working capital ÷ total assets + 3.26 × retained earnings ÷ total assets + 6.72 × EBIT ÷ total assets + 1.05 × book equity ÷ total liabilities (Altman, Hartzell and Peck, 1995), the variant for non-manufacturing and asset-light companies.
| Zone | Z | Z″ |
|---|---|---|
| Safe zone | above 2.99 | above 2.60 |
| Grey zone | 1.81–2.99 | 1.10–2.60 |
| Distress zone | below 1.81 | below 1.10 |
Not worked out for banks, insurers and REITs, whose balance sheets the model does not describe, nor when a figure is missing or there is no share price in the week to the fiscal year end.
Altman Z-score against peers
| Company | Altman Z-score |
|---|---|
| GRCE Grace Therapeutics, Inc. | 3.3× |
| VERU Veru Inc. compare | −5.8× |
| CELU Celularity, Inc. compare | −15.2× |
| SGMOQ Sangamo Therapeutics, Inc. compare | −43.3× |
| LBPS 4D pharma PLC Sponsored ADR compare | — |
| ANVS Annovis Bio, Inc. compare | — |
| ALDX Aldeyra Therapeutics, Inc. compare | — |
| DWTX Dogwood Therapeutics, Inc compare | — |
| TIL Instil Bio, Inc. compare | — |
What Altman Z-score is
The Altman Z-Score weighs working capital, retained earnings, operating profit, market value and sales against assets and debts to gauge the risk of distress.
1.2 × working capital ÷ total assets + 1.4 × retained earnings ÷ total assets + 3.3 × EBIT ÷ total assets + 0.6 × market value of equity ÷ total liabilities + 1.0 × revenue ÷ total assets